Relationship between patient-reported outcomes and clinical outcomes in patients with morquio a syndrome

Journal of Inborn Errors of Metabolism and Screening

Volumn 2015, Issue , 2015, Pages

  Lampe, Christina ^a   Jain, Mohit ^b   Olaye, Andrew ^b   Meesen, Bianca ^c   Decker, Celeste ^b   Mengel, Eugen ^d  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

^c Ismar Healthcare   (Belgium)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

3MSC test; 6MWT; EQ5D 5L; FVC; Maximal voluntary ventilation; Mobility; Morquio A; Mucopolysaccharidosis IV; Patient reported outcomes; Patient s perception; Physical endurance; Quality of life; Respiratory function tests

Indexed keywords

3 MINUTE STAIR CLIMB TEST; 6 MINUTE WALK TEST; ADOLESCENT; ADULT; ARTICLE; CHILD; CROSS-SECTIONAL STUDY; ENDURANCE; EXPERIMENTAL TEST; FEMALE; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MALE; MAXIMUM VOLUNTARY VENTILATION; MIDDLE AGED; MORQUIO SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANGE OF MOTION; SCORING SYSTEM; SPIROMETRY; YOUNG ADULT;

EID: 84984597051     PISSN: 23264098     EISSN: 23264594     Source Type: Journal    
DOI: 10.1177/2326409815576188     Document Type: Article

References (29)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8 ed. New York: McGraw-Hill Medical Publishing Division; 2001:3421-3452
2. Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109(1):54-61
3. Hendriksz CJ, Al-Jawad M, Berger KI, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis. 2013;36(2):309-22
4. Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinicalmanifestation and natural course of Morquio A disease. J InheritMetab Dis. 2007;30(2):165-174
5. Tomatsu S, Montaño AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12(6):931-945
6. Mocellin R. Exercise testing in children with congenital heart disease. Pediatrician. 1986;13(1):18-25
7. McArdle WD, Katch FI, Katch VL. The Physiologic Support Systems. Essentials of Exercise Physiology, Third ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:290-431
8. McDonald A, Steiner R, Kuehl K, Turbeville S. Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr Rehabil Med. 2010;3(2):119-127
9. Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patientreported outcomes: A new era in clinical research. Perspect Clin Res. 2011;2(4):137-144
10. Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10(suppl 2):S125-S137
11. Food and Drug Administration (2009). Guidance for industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. US: Food and Drug Administration.
12. Santos JJAD, Plewka JEA, Brofman PRS. Quality of life and clinical indicators in heart failure: a multivariate analysis. Arq Bras Cardiol. 2009;93(2):149-156
13. Saad IAB, Botega NJ, Toro IFC. Predictors of quality-of-life improvement following pulmonary resection due to lung cancer. Sao Paulo Med J. 2007;125(1):46-49
14. Henricson E, Abresch R, Han JJ, et al. The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr. 2013;5
15. Hendriksz CJ, Lavery C, Coker M, et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32
16. EuroQol Group.EQ-5D-5L UserGuide.Web site. http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-5.pdf> Accessed February 2014. EuroQol Group. EQ-5D-5L User Guide. Web site. http://www.euroqol.org/about-eq-5d/valuation-of-eq-5d.html Accessed February 2014
17. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzymereplacement therapy of mucopolysaccharidosis VI (Maroteaux- Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115(6):e681-e689
18. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338
19. Tylki-Szymanska A, Marucha J, Jurecka A, Syczewska M, Czartoryska B. Efficacy of recombinant human a-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis. 2010;33(2):151-157
20. Gerhardt JJ, Rondinelli RD. Goniometric techniques for range-ofmotion assessment. PhysMedRehabil ClinNAm. 2001;12(3):507-527
21. Li AM, Yin J, Au JT, et al. Standard reference for the six-minutewalk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med. 2007;176(2):174-180
22. Casanova C, Celli BR, Barria P, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J. 2011;37(1):150-156
23. Web site. http://www.cdc.gov/niosh/topics/spirometry/refcalculator.html. Last updated: July 2010, last accessed: February 2015
24. Montaño AM, Tomatsu S, Brusius A, Smith M, Orii T. Growth charts for patients affected with Morquio A disease. Am J Med Genet A. 2008;146A(10):1286-1295
25. Brown CD, Benditt JO, Sciurba FC, et al. Exercise testing in severe emphysema: association with quality of life and lung function. COPD. 2008;5(2):117-124
26. Han B, Yan B, Zhao N, et al. The influence of the functional capacity on subjective well-being and quality of life of patients with silicosis. Aging Ment Health. 2013;17(6): 707-713
27. Heuker D, Lengele B, Delecluse V, et al. Subjective and objective assessment of quality of life after chest wall resection. Eur J Cardiothorac Surg. 2011;39(1):102-108
28. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469
29. Hendriksz CJ, Lavery C, Coker M, et al. The burden endured by caregivers of patients with morquio a syndrome: results from an international patient-reported outcomes survey. J Inborn Error Metab Screen. 2014;2:1-8.